Grifols (GRFS) to Release Earnings on Wednesday

Grifols (NASDAQ:GRFS) is expected to post its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect the company to announce earnings of $0.29 per share and revenue of $1.9551 billion for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, March 5, 2026 at 3:00 AM ET.

Grifols Stock Down 3.5%

Shares of Grifols stock opened at $9.07 on Tuesday. Grifols has a 52-week low of $6.19 and a 52-week high of $11.14. The company’s 50-day simple moving average is $9.21 and its 200-day simple moving average is $9.38. The company has a current ratio of 2.48, a quick ratio of 0.93 and a debt-to-equity ratio of 1.20.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. EverSource Wealth Advisors LLC grew its stake in Grifols by 127.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 8,219 shares of the biotechnology company’s stock valued at $74,000 after acquiring an additional 4,604 shares during the last quarter. Ameriprise Financial Inc. acquired a new position in Grifols during the second quarter worth about $95,000. Ieq Capital LLC purchased a new stake in shares of Grifols in the fourth quarter valued at about $154,000. Creative Planning grew its position in shares of Grifols by 15.0% in the third quarter. Creative Planning now owns 16,414 shares of the biotechnology company’s stock valued at $163,000 after purchasing an additional 2,141 shares during the last quarter. Finally, Cerity Partners LLC increased its stake in shares of Grifols by 6.3% during the 4th quarter. Cerity Partners LLC now owns 19,121 shares of the biotechnology company’s stock worth $179,000 after purchasing an additional 1,131 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on GRFS. JPMorgan Chase & Co. dropped their target price on Grifols from $10.30 to $10.00 and set a “neutral” rating on the stock in a research report on Monday, December 8th. Weiss Ratings restated a “hold (c)” rating on shares of Grifols in a research note on Thursday, January 22nd. Wall Street Zen upgraded Grifols from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 15th. Finally, Zacks Research raised Grifols from a “strong sell” rating to a “hold” rating in a report on Friday, February 6th. Four investment analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $10.00.

About Grifols

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.